Centro Cardiologico Monzino

It is the first and biggest European centre for care, learning and research solely dedicated to the heart. And also a landmark for new therapies and the avantgarde of clinical and scientific research

È il primo e più grande centro di cura, formazione e ricerca in Europa esclusivamente dedicato al cuore. E un punto di riferimento nazionale e internazionale per le nuove terapie e l’avanguardia della ricerca clinica e scientifica

Mauro Melis

Mauro Melis

The Monzino Cardiology Centre was born out of a “question of the heart”. Italo Monzino – an entrepreneur from Milan and member of the knowledgeable and solid middle class that made history in the capital of Lombardy – decided at the beginning of the 1980s that the people of Milan needed “a hospital for the heart”. The idea was brought to life thanks to a meeting with Professor Cesare Bartorelli who made the project even more ambitious: the Cardiology Centre had to be affiliated with a university and the number one heart surgery learning site in Milan.

The ultra-modern centre dedicated exclusively to cardiovascular diseases was opened in 1981 and included as part of the National Health Service in Italy. In 1992, it obtained the status of a Scientific Institute of Research and Health Care. Today it is the biggest and best centre for health care, learning and research in Europe that is dedicated solely to the heart. In 2000, the Monzino Centre was acquired by the European Institute of Oncology founded by Umberto Veronesi; together the two centres tackle the main causes of diseases in the world.

The Monzino Centre is centred on innovation and training the doctors of the future. Located on Via Carlo Parea in the east of Milan, it is a national and international reference point for new therapies and cutting-edge clinical and scientific research. Its uniqueness lies in the specialisation that has made the Monzino Centre a permanent laboratory for experimenting with the new frontiers of cardiology. If there's an innovative technology or new treatment anywhere in the world, it's available at the Monzino Centre.

This focus on the future has paved the way for illuminating and even courageous choices, such as the one to set up one of the most advanced cardiovascular imaging sites in Europe or install the first multi-functional operating theatre in Italy in 2007, where the patient can simultaneously receive different types of treatment: surgical, interventional and arrhythmological. This choice is in line with the latest clinical evolution which is moving towards a new kind of cardiovascular medicine – ultra-specialised but at the same time able to offer interdisciplinary and across-the-board knowledge.

The vocation for innovation is also supported by the close bond with the University of Milan: the Monzino Cardiology Centre is the main site for undergraduate and postgraduate learning in cardiology and heart surgery. Each specialisation has its own specific school, as well as a course on circulatory pathophysiology and cardiovascular perfusion techniques.

Cutting-edge specialisation and high technology usage is accompanied by a strong human investment in the relationship between doctor and patient. You can safely say that the Monzino Centre has written its page in the history of cardiology and heart surgery both in Italy and in some parts of the world, contributing to creating a culture of medicine and a relationship with the patient, who is welcomed and cared for as a person in their entirety.

In 2014 at the Monzino Centre, around 1500 cardiovascular operations were carried out, as well as more than 4000 cardiological intervention procedures. These included inserting around 2000 coronary angioplasty stents. Furthermore, approximately 2500 patients were treated with electrophysiology procedures to address problems in the heart's rhythm. Clinical results from the Monzino Cardiology Centre – in terms of mortalities and complications – put it at the top of international rankings for curing cardiovascular diseases in adults, as well as research with more than 170 publications in scientific journals (an Impact Factor of around 1000), 160 research projects currently under way and 60 clinical trials.